6533b872fe1ef96bd12d3941

RESEARCH PRODUCT

A Case of Epididymo-orchitis after intravesical bacille Calmette-Guérin therapy for superficial bladder carcinoma in a patient with latent tuberculosis infection

Marcello TrizzinoAntonio CascioLucia SiracusaGiuliana GuadagninoClaudia GioèClaudia ColombaP. Di Carlo

subject

medicine.medical_specialtyCancer ResearchComplicationsSettore MED/17 - Malattie InfettiveEpidemiologyBladder030232 urology & nephrologyUrologyShort ReportInfectious DiseaseGastroenterologySepsis03 medical and health sciences0302 clinical medicineInternal medicinemedicineGranulomatous prostatitisBladder; Calmette; Complications; Guérin; Intravesical; Infectious Diseases; Oncology; Epidemiology; Cancer ResearchPneumonitisHepatitisLatent tuberculosisbusiness.industryIntravesicalIsoniazidmedicine.diseaseInfectious DiseasesOncology030220 oncology & carcinogenesisOrchitisSuperficial Bladder CarcinomabusinessComplicationGuérinmedicine.drugCalmette

description

Background: Intravesical instillation of bacille Calmette-Guérin (BCG) has been established as efficient therapy for superficial bladder carcinoma. Overall, intravesical BCG is well tolerated and results in complications of less than 5 %. However, adverse effects such as granulomatous prostatitis, pneumonitis, hepatitis, sepsis, and hypersensitivity reactions may occur. The reported rate for tuberculous orchitis after BCG intravesical therapy is 0.4 %. Findings: We report a case of monolateral tuberculous orchitis occurring one month after the second course of intravescical instillation of bacille Calmette-Guérin in a patient with proven superficial bladder carcinoma and latent tuberculosis infection. Conclusions: In our opinion intravesical instillation of BCG should be considered on an individual patient basis, with full patient disclosure of the potentially significant risks. A screening with an intradermal Mantoux before starting the first cycle of BCG instillation should be recommended and isoniazid would be indicated as the treatment for latent tuberculosis infection.

10.1186/s13027-016-0072-yhttp://europepmc.org/articles/PMC4890504